SOURCE: MELA Sciences

MELA Sciences

December 28, 2010 08:00 ET

MELA Sciences to Present at 13th Annual Needham Growth Conference

IRVINGTON, NY--(Marketwire - December 28, 2010) - MELA Sciences, Inc. (NASDAQ: MELA) announced today that Joseph V. Gulfo, MD, President and CEO, will present at the 13th Annual Needham Growth Conference at The New York Palace Hotel in New York City.

Dr. Gulfo's presentation is scheduled for Wednesday, January 12, 2011 at 10:40 am ET. To access a live webcast of this presentation, visit the investor relations section of www.melasciences.com. A replay will be available on the company's website for two weeks following the presentation.

About MELA Sciences

MELA Sciences is a medical technology company focused on developing MelaFind®. MelaFind® is a non-invasive and objective multi-spectral computer vision system designed to aid physicians in the detection of early melanoma from among clinically atypical (those having one or more clinical or historical characteristics of melanoma, such as asymmetry, border irregularity, color variegation, diameter greater than 6 millimeters, evolving, patient concern, regression, and ugly duckling) cutaneous pigmented lesions that are non-ulcerated, not bleeding, and less than 2.2 centimeters in diameter, when a physician chooses to obtain additional information before making a final decision to biopsy to rule out melanoma.

The MelaFind® Pre-Market Approval (PMA) application was filed with the U.S. Food and Drug Administration (FDA) in June 2009 and is currently under review at the FDA. On November 18, 2010 the General and Plastic Surgery Devices Panel, appointed by the U.S. Food and Drug Administration (FDA), voted by majority that, for its proposed indications, MelaFind® is safe and effective and that its benefits outweigh the risks. The FDA will take into account, among other things, the panel's recommendation in making its final approval decision. The FDA has not provided a date as to when it will make a decision regarding the MelaFind® PMA application. FDA approval is required prior to marketing MelaFind® in the United States.

For more information on MELA Sciences, visit www.melasciences.com.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "may," "will," "should," "estimates," "expects," "contemplates," "anticipates," "plans," "intends," "believes" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to economic, business, competitive, market and regulatory factors. We base our forward-looking statements on information currently available to us, and we assume no obligation to update them.

Contact Information

  • For further information contact:

    For Investors:
    David Carey
    Lazar Partners, Ltd.
    646-871-8485

    For Media:
    Hollister Hovey
    Lazar Partners, Ltd.
    646-871-8485